ZURICH (AFX) - Roche Holding AG said it has teamed up with BioCryst Pharmaceuticals Inc to develop and commercialise BioCryst's phase I compound BCX-4208 for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.
Roche will obtain worldwide rights to BCX-4208 in exchange for a 25 mln usd up-front payment and a 5 mln payment as reimbursement for supply of material during the first 24 months of the collaboration.
Future event payments could reach 530 mln usd in addition to royalties on product sales of BCX-4208.
afx.zurich@afxnews.com
scs/lam
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
Roche will obtain worldwide rights to BCX-4208 in exchange for a 25 mln usd up-front payment and a 5 mln payment as reimbursement for supply of material during the first 24 months of the collaboration.
Future event payments could reach 530 mln usd in addition to royalties on product sales of BCX-4208.
afx.zurich@afxnews.com
scs/lam
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved.
The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
© 2005 AFX News
